Compare Estee Lauder Companies Inc (EL) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Enveric Biosciences Inc — how do they compare? Estee Lauder Companies Inc trades at $98.17 (market cap $34.17B), while Enveric Biosciences Inc trades at $1.48 (market cap $6.80M). The key difference: Estee Lauder Companies Inc is far larger — about 5025× Enveric Biosciences Inc's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Enveric Biosciences Inc for 14 Days on average.
| EL | ENVB | |
|---|---|---|
Market Cap | $34.17B | $6.80M |
Volume | 3,921,497 | 64,867 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $10.80 |
52-Week Low | $67.23 | $1.27 |
Typical Hold Time | 122 Days | 14 Days |
Enterprise Value | $39.92B | -$1.49M |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $97.81, up 3.56% with recent earnings beats but faces fundamental challenges including a net loss of $1.13B in 2025. The stock shows neutral technical signals with support at $90 and resistance at $98, while analyst consensus remains positive with a $103 price target. Recent developments include AI partnerships and leadership changes aimed at revitalizing the brand.
The outlook hinges on margin recovery and revenue stabilization, with 2026 projections showing a return to profitability. Key risks include competitive pressures and execution of turnaround strategy, but institutional sentiment remains cautiously optimistic given the company's strong brand portfolio and digital initiatives.
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
